Cell, Gene and Therapy Journal

Peer-reviewed multi-disciplinary and Open Access journal accepts scientifically rigorous research, regardless of novelty

Introduction

Journal of Cell, Gene and Therapy is a peer-reviewed multi-disciplinary and Open Access journal accepts scientifically rigorous research, regardless of novelty. CGT’s broad scope provides a platform to publish basic and clinic research, including interdisciplinary and replication studies as well as negative results. The journal’s publication criteria are based on high ethical standards and the rigor of the methodology and conclusions reported. Specific scientific topics of interest to the journal include, but are not limited to:

  • gene and cell study
  • stem cell therapy
  • Genetics
  • pharmaceutics
  • medicinal biochemistry
  • clinical investigation
  • biotechnology
  • nanotechnology
  • clinical trial.

About the Journal

Journal of Cell، Gene and Therapy (CGT) is a peer-reviewed multi-disciplinary and Open Access journal accepts scientifically rigorous research which is edited by a scientific editorial board.

CGT’s broad scope provides a platform to publish basic and clinic research, including interdisciplinary and replication studies as well as negative results. Scientific topics of interest to the journal include, but are not limited to: gene and cell study, stem cell therapy, Genetics, pharmaceutics, medicinal biochemistry, clinical investigation, biotechnology, nanotechnology, and clinical trials.

CGT released the first issue on April the first 2019 and the second issue is going to be released in July 2019 as well.

We would be very delighted to receive your Original papers, Review Articles, Short communications, Case reports, and Scientific Letters to the Editor on the above-mentioned research areas and we are able to evaluate the received manuscripts and publish them quiet shortly.

Scope

We will also consider the following article types:

  • Systematic reviews. We consider publishing systematic reviews only if the methods ensure the comprehensive and unbiased sampling of existing literature.
  • Submissions describing methods, software, databases, or other tools. We consider submissions describing methods, software, databases, or other tools if they follow the appropriate reporting guidelines.
  • Qualitative research. We consider publishing qualitative research only if it adheres to appropriate study design and reporting guidelines.
  • Clinical study. We consider publishing clinical reports, such as case report, pre-clinical study, clinical trials which are based on the ethical procedures.
  • Studies reporting negative results

Authors Guidlines

Submit Your Manuscript

For more information about submitting to CGT, read our checklist for getting started and our guidelines for preparing a submission.

 

MANUSCRIPT PREPARATION

Manuscripts should be prepared in accordance with the “Uniform Requirements for Manuscripts Submission to Cell, Gene and Therapy (CGT) ” proclaimed by the International Committee of Medical Journal Editors. Language. Manuscripts should be in English (either British or American spelling). The past tense should be used throughout in describing the results, and the present tense in referring to previously established and generally accepted results. Authors who are unsure of correct English editing should have their manuscript checked by those proficient in the language; manuscripts that are deficient in this respect may be returned to the author for revision before scientific review.

 

Type setting

Manuscripts must be typewritten in Times New Roman with a font size of 12 points, double-spaced (including References, Tables and Figure legends) with 2.5 cm margins from each side. All pages should be numbered consecutively at the bottom starting with the title page. Length. The maximum length for describing methods, full length papers, reviews an Clinical study (including tables, figures and references) should not exceed 3000, 4500,  6000  and 4500 words, respectively. Any repetition of information in the text and illustrations and excessively list of references must be avoided.

 

GENERAL ARRANGEMENT OF PAPERS

Title

Titles must be concise and informative. The title should be followed by the authors' full (first, middle and last) names and their affiliations (identified by use of Arabic numbers (1, 2, 3, etc.) in superscript format next to the authors’names.

 

Running Title

The text should include a running title of no more than 30 characters including spaces.

 

Footnotes

The name and full postal address, telephone, fax and E-mail number of corresponding author should be provided in a footnote.

 

Abbreviations

 The Journal publishes a standard list of abbreviations at the beginning of every issue. These

standard abbreviations do not need to be spelled out within paper. However, non-standard and undefined abbreviations used five or more times should be listed in the footnote. Abbreviations should be defined where first mentioned in the text. Do not use abbreviations in the title, but they can be used in the Figures and Tables with their description in the figure legend or table footnote.

 

Abstract

 Abstract should follow the title (excluding the authors’ names) on the second page. Abstracts must be written in a structured (Background, Methods, Results, and Conclusion) format, at a maximum of 150 or 250 words for short communications and full papers, respectively. Inclusion of  references must be avoided in the abstracts.

 

Keywords

Three to five keywords for indexing should be included at the foot of the abstract chosen from the Medical Subject Headings (MeSH).

 

Introduction

This should contain a description of the problem under investigation and a brief survey of the

existing literature on the subject.

Materials and Methods

Sufficient details must be provided to allow for the reproduction of the work. Complete

and accurate names of materials, including chemical and organisms, should be specified followed by the suppliers’ information (in parenthesis). System International (SI) units and symbols must be used.

 

Results

 This section should concisely describe the rationale of the investigation and its outcomes. Data should not be replicated in the text, tables or figure.

 

Discussion

 This section should relate the results to the previous pertinent reports report and provide potential interpretations.

 

Acknowledgments

Grant support should be included in this section. It may also include the expression of

gratitude towards contributors, not included in the authors’ list.

 

Ethical Guidelines

Animal and human experimental studies must follow the international guidelines and declarations as well as regulations enforced by the local ethical committees of the countries where the research is done. Experiments on human individuals must be performed after obtaining a signed written informed consent form the subject or his/her

guardian. CGT reserves the right to reject papers based on ethical considerations when the scientific value of the

research does not justify the methods used in the study

Open Access

CGT facilitate open access – namely, free immediate access to, and unrestricted reuse of, original works of all types.

Publication Fees

CGT publication is free.

Contact

Visit the Contact page for details about whom to contact with different queries.

Give Feedback

Our Team

Dr. Saeed Shahbeigi

Chairman

“Neurologist and Neuroimmunologist, Brain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Neuroscience Research Center, Iran University of Medical Sciences, President of Stem cell Association of Tehran-Iran”

Dr. Saeed Shahbeigi Chairman

Prof. Abolfazl Movafagh

Editor-in-chief

“Head of Department of Medical Genetics of Shahid Beheshti Medical University. Vice President society of Medical Genetics Department”

Prof. Abolfazl Movafagh Editor-in-chief

Mohammad Amin Habibi

Internal Manager

“Medical Student in Medical University Of Qom”

Mr. Mohammad Amin Habibi Internal Manager

Editorial Board

  • Chairman

  • Dr Saeed Shahbeigi

    Neurologist and Neuroimmunologist, Brain Mapping Research Centre, Shahid Beheshti University of Medical Sciences, Neuroscience Research Centre, Iran University of Medical Sciences, President of Stem cell Association of Tehran-Iran

  • Editor-in-Chief

  • Prof. Abolfazl Moafagh

    Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran

  • Executive Manager

  • Dr Sima Kianpour Rad

    Faculty of Medicine, Department of Molecular medicine, University of Malaya, kuala Lumpur, malaysia

  • Advisory Editorial Board

  • Dr. Hesam Abdolhoseinpour
    Dr. Mohammad Ali Arami
    Prof. Arbabi
    Prof. Ayse Altintas
    Dr. Mandana Moheddin Bonab
    Dr. Gholamreza Bakhshandepour
    Prof. Korosh Gharegozli
    Prof. Mohammad Hassan Heidari
    Dr. Seid Mohammad Taghi Hoseini Tabatabaee
    Prof. Behnam Jamei
    Dr. Mohammad Karimi
    Dr. Ahmad Khatoon Abadi
    Dr. Behnam Mansoori
    Prof. Alireza Mesbahi
    Prof. Abolfazl Moafagh
    Prof. Afshin Moradi
    Dr. Abbas Najari
    Dr. Hafez Norozizadeh
    Prof. Mina Ohadi
    Prof. Hosein pakdaman
    Dr. Ali Akbar Safar Moghadam
    Dr. Sasan Saket
    Dr. Saeed Shahbeigi
    Prof. Mesbah Shams
    Dr. Mojgan Sheikhpour
    Prof. Ali Zali
    Prof. Mahdi Zamani

Journal of Cell, Gene and Therapy

peer-reviewed multi-disciplinary and Open Access journal accepts scientifically rigorous research, regardless of novelty

Subcribe to our Newsletter

Get in touch with us



Recent Articles

Effect of serum ferritin level on pulmonary dysfunction and sensitisation to aeroallergens in paediatric beta thalassemia major


Soheila Kianpour Rad 1*, Seyed Mohammad Fathi 2, Hadi Mousakhani 3 1 Qazvin University of Medical Science, Qazvin, Iran 2 Allergist& Clinical Immunologist ,Children Growth Research Center, Qazvin University of Medical Sciences, Qazvin, Iran 3 Hematologist & Oncologist,Children Growth Research Center, Qazvin University of Medical Sciences, Qazvin, Iran

The beta thalassemia major (BTM) is the most severe type of thalassemia. Outlining steps in such health problems are vital, since affected children who need repeated transfusions undergo deposition of iron in their different body tissue, causing various dysfunctions, including lung impairment. 33 BTM patients were examined by Pulmonary Function Tests (PFTs) and also skin Prick test and the serum ferritin level was checked. The study demonstrated that 60.5% of the patients had normal PFTs, 21.33% showed restrictive, 12.12% obstructive pattern and two (6.06%) had the mixed pattern and the predominant pulmonary dysfunction was restrictive. Severity of the restrictive pattern has significant correlation with serum ferritin level but not with age, sex, Body Mass Index (BMI) and duration of transfusion therapy. The majority of Splenectomised (SPL) patients had restrictive pattern. Only 5 patients had positive prick test which shows that BTM did not relate to their positive prick test. Cell, Gene and Therapy, Vol.1, Number 1, April 1st, 2019; 64-72

Evaluating the effect of intravenous immunoglubin in neonatal hemolytic jaundice caused by Rh and ABO isoimmunization


Masoumeh Hematyar1, Mehdi Zareian2 1Associate professor of “Pediatrics”, Islamic Azad University, Tehran Medical Branch 2General practitioner, Islamic Azad University, Tehran Medical Branch

History & Background: Several studies have shown that prescribing intravenous immunoglobulin(IVIG) can reduce the severity of neonatal hemolytic jaundice due to Rh and ABO incompatibility as well as the need for exchange transfusion. The present study aimed to evaluate the effect of IVIG in treatment of neonatal hemolytic jaundice caused by Rh and ABO isoimmunization. Methods: This clinical trial study was conducted on 80 newborns with neonatal hemolytic jaundice caused by Rh and ABO isoimmunization hospitalized in the neonatal ward of Mahdieh Hospital in Tehran, Iran from 2017 to 2018. The infants were randomly assigned to case (phototherapy and IVIG) and control (phototherapy) groups. IVIG was prescribed with the dosage of 500mg/kg during 4 hours and which could be repeated for 3 doses, if required. The severity of jaundice, duration of hospitalization for phototherapy , need for exchange transfusion and IVIG complications were studied and recorded in all patients. The data were analyzed using SPSS software, Chi square and independent T-tests. Results: In patients who received both IVIG and phototherapy, the duration of phototherapy and hospitalization as well as the need for exchange transfusion were significantly lower than the control group. No IVIG complications were observed. Conclusion: Prescribing IVIG is an effective and safe treatment that can reduce the severity of jaundice , the need for exchange transfusion and duration of phototherapy in neonatal hemolytic jaundice due to Rh and ABO incompatibility. Cell, Gene and Therapy, Vol.1, Number 1, April 1st, 2019; 24- 28

The Therapeutic Roles of TAZ biomarker [WWTR1] in Cancer


Mahsa Mohammadzadeh1, Mehrdad Hashemi1*, Babak Negahdari2, 3 , Fatemeh Ghaemimanesh2 1 Faculty of advanced sciences and technology, Department of Genetics, Islamic Azad University, Tehran Medical Sciences , Tehran, Iran 2 Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran 3 Department of Medical Biotechnology, School of Advanced Science in Medicine, Tehran University of Medical Science, Tehran, Iran

Many studies show the role of TAZ biomarkers in multiple malignancies. This study has focused on the significance of TAZ biomarker (WWTR1) in diagnosis or development of multiple cancers such as lung cancer, ovarian cancer, colorectal cancer, and breast cancer. The use of biomarkers is now a new way of detecting many diseases, such as cancer. This way, for instance, more than 90% of ovarian cancers are diagnosed in their early stage. This research is included in the results of the related articl

Clinical Manifestations of Anti-NMDAR Encephalitis: Western Canadian Case Series and Practical Recommendations for Treatment


Saeed Shahbeigi [Brain Mapping Research Centre, Shahid Beheshti University of Medical Sciences, Neuroscience Research Center, Iran University of Medical Sciences], Amir Ali Sepehry [Faculty of Medicine, Division of Neurology, University of British Columbia, Vancouver, Canada] , Joel Oger [Emeritus Professor of University of British Columbia]

Anti-NMDAR encephalitis is a life threatening yet treatable neuroimmune disease secondary to the presence of autoantibodies. Despite a growing body of literature, this disorder remains under-recognized, due to variable presentations, and limited clinicians familiarity with the condition. Methods: We describe three cases that were diagnosed at Vancouver General Hospital, Canada. Results: Case 1, a 23-year old Caucasian woman presented with low-grade fever, personality changes, and status epilepticus. She had a normal brain MRI and CSF markers. Anti-NMDAR (NR1) was positive in serum. She had bilateral ovarian teratomas. After oophorectomy and immunosuppressive treatments, the NMDAR antibodies became negative and her seizures completely disappeared. Case 2, following delivery, a 27-year Chinese woman rapidly developed sudden significant behavioural changes, and seizure. She had a teratoma and positive NMDAR (NR1) in the CSF and serum. Despite bilateral oophorectomy and receiving high doses of immunosuppression, she has developed severe sequelae. Case 3, a 32-year Philippino-Canadian female developed short-term memory problems, olfactory hallucinations, and orofacial dyskinesia for 2 years. After receiving steroids, PLEX and IVIG, she clinically improved markedly without any sequel. It is important to mention, on the paper we talk about the first and second line of therapy and interestingly a new treatment option called Bortizomib for refractory NMDAR patients to 1st and 2nd line of therapy as well. Conclusion: Based on our experience when the diagnosis of the anti-NMDAR encephalitis is made in the presence of normal brain MRI and CSF the prognosis is better